Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells

Eva Nievergall, Hayley S. Ramshaw, Agnes S M Yong, Mark Biondo, Samantha J. Busfield, Gino Vairo, Angel F. Lopez, Timothy P. Hughes, Deborah L. White, Devendra K. Hiwase

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Despite the remarkable efficacy of tyrosine kinase inhibitors (TKIs) in eliminating differentiated chronic myeloid leukemia (CML) cells, recent evidence suggests that leukemic stem and progenitor cells (LSPCs) persist long term, which may be partly attributable to cytokine-mediated resistance. We evaluated the expression of the interleukin 3 (IL-3) receptor α subunit (CD123), an established marker of acute myeloid leukemia stem cells, on CML LSPCs and the potential of targeting those cells with the humanized anti-CD123 monoclonal antibody CSL362. Compared with normal donors, CD123 expression was higher in CD34+/CD38- cells of both chronic phase and blast crisis CML patients, with levels increasing upon disease progression. CSL362 effectively targeted CML LSPCs by selective antibody-dependent cell-mediated cytotoxicity (ADCC)-facilitated lysis of CD123+ cells and reduced leukemic engraftment in mice. Importantly, not only were healthy donor allogeneic natural killer (NK) cells able to mount an effective CSL362-mediated ADCC response, but so were CML patients' autologous NK cells. In addition, CSL362 also neutralized IL-3-mediated rescue of TKI-induced cell death. Notably, combination of TKI- and CSL362-induced ADCC caused even greater reduction of CML progenitors and further augmented their preferential elimination over normal hematopoietic stem and progenitor cells. Thus, our data support the further evaluation of CSL362 therapy in CML.

LanguageEnglish
Pages1218-1228
Number of pages11
JournalBlood
Volume123
Issue number8
DOIs
Publication statusPublished - 20 Feb 2014

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Nievergall, Eva ; Ramshaw, Hayley S. ; Yong, Agnes S M ; Biondo, Mark ; Busfield, Samantha J. ; Vairo, Gino ; Lopez, Angel F. ; Hughes, Timothy P. ; White, Deborah L. ; Hiwase, Devendra K. / Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. In: Blood. 2014 ; Vol. 123, No. 8. pp. 1218-1228.
@article{42923c47c3524f2fb323e280889ee0a3,
title = "Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells",
abstract = "Despite the remarkable efficacy of tyrosine kinase inhibitors (TKIs) in eliminating differentiated chronic myeloid leukemia (CML) cells, recent evidence suggests that leukemic stem and progenitor cells (LSPCs) persist long term, which may be partly attributable to cytokine-mediated resistance. We evaluated the expression of the interleukin 3 (IL-3) receptor α subunit (CD123), an established marker of acute myeloid leukemia stem cells, on CML LSPCs and the potential of targeting those cells with the humanized anti-CD123 monoclonal antibody CSL362. Compared with normal donors, CD123 expression was higher in CD34+/CD38- cells of both chronic phase and blast crisis CML patients, with levels increasing upon disease progression. CSL362 effectively targeted CML LSPCs by selective antibody-dependent cell-mediated cytotoxicity (ADCC)-facilitated lysis of CD123+ cells and reduced leukemic engraftment in mice. Importantly, not only were healthy donor allogeneic natural killer (NK) cells able to mount an effective CSL362-mediated ADCC response, but so were CML patients' autologous NK cells. In addition, CSL362 also neutralized IL-3-mediated rescue of TKI-induced cell death. Notably, combination of TKI- and CSL362-induced ADCC caused even greater reduction of CML progenitors and further augmented their preferential elimination over normal hematopoietic stem and progenitor cells. Thus, our data support the further evaluation of CSL362 therapy in CML.",
author = "Eva Nievergall and Ramshaw, {Hayley S.} and Yong, {Agnes S M} and Mark Biondo and Busfield, {Samantha J.} and Gino Vairo and Lopez, {Angel F.} and Hughes, {Timothy P.} and White, {Deborah L.} and Hiwase, {Devendra K.}",
year = "2014",
month = "2",
day = "20",
doi = "10.1182/blood-2012-12-475194",
language = "English",
volume = "123",
pages = "1218--1228",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. / Nievergall, Eva; Ramshaw, Hayley S.; Yong, Agnes S M; Biondo, Mark; Busfield, Samantha J.; Vairo, Gino; Lopez, Angel F.; Hughes, Timothy P.; White, Deborah L.; Hiwase, Devendra K.

In: Blood, Vol. 123, No. 8, 20.02.2014, p. 1218-1228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells

AU - Nievergall, Eva

AU - Ramshaw, Hayley S.

AU - Yong, Agnes S M

AU - Biondo, Mark

AU - Busfield, Samantha J.

AU - Vairo, Gino

AU - Lopez, Angel F.

AU - Hughes, Timothy P.

AU - White, Deborah L.

AU - Hiwase, Devendra K.

PY - 2014/2/20

Y1 - 2014/2/20

N2 - Despite the remarkable efficacy of tyrosine kinase inhibitors (TKIs) in eliminating differentiated chronic myeloid leukemia (CML) cells, recent evidence suggests that leukemic stem and progenitor cells (LSPCs) persist long term, which may be partly attributable to cytokine-mediated resistance. We evaluated the expression of the interleukin 3 (IL-3) receptor α subunit (CD123), an established marker of acute myeloid leukemia stem cells, on CML LSPCs and the potential of targeting those cells with the humanized anti-CD123 monoclonal antibody CSL362. Compared with normal donors, CD123 expression was higher in CD34+/CD38- cells of both chronic phase and blast crisis CML patients, with levels increasing upon disease progression. CSL362 effectively targeted CML LSPCs by selective antibody-dependent cell-mediated cytotoxicity (ADCC)-facilitated lysis of CD123+ cells and reduced leukemic engraftment in mice. Importantly, not only were healthy donor allogeneic natural killer (NK) cells able to mount an effective CSL362-mediated ADCC response, but so were CML patients' autologous NK cells. In addition, CSL362 also neutralized IL-3-mediated rescue of TKI-induced cell death. Notably, combination of TKI- and CSL362-induced ADCC caused even greater reduction of CML progenitors and further augmented their preferential elimination over normal hematopoietic stem and progenitor cells. Thus, our data support the further evaluation of CSL362 therapy in CML.

AB - Despite the remarkable efficacy of tyrosine kinase inhibitors (TKIs) in eliminating differentiated chronic myeloid leukemia (CML) cells, recent evidence suggests that leukemic stem and progenitor cells (LSPCs) persist long term, which may be partly attributable to cytokine-mediated resistance. We evaluated the expression of the interleukin 3 (IL-3) receptor α subunit (CD123), an established marker of acute myeloid leukemia stem cells, on CML LSPCs and the potential of targeting those cells with the humanized anti-CD123 monoclonal antibody CSL362. Compared with normal donors, CD123 expression was higher in CD34+/CD38- cells of both chronic phase and blast crisis CML patients, with levels increasing upon disease progression. CSL362 effectively targeted CML LSPCs by selective antibody-dependent cell-mediated cytotoxicity (ADCC)-facilitated lysis of CD123+ cells and reduced leukemic engraftment in mice. Importantly, not only were healthy donor allogeneic natural killer (NK) cells able to mount an effective CSL362-mediated ADCC response, but so were CML patients' autologous NK cells. In addition, CSL362 also neutralized IL-3-mediated rescue of TKI-induced cell death. Notably, combination of TKI- and CSL362-induced ADCC caused even greater reduction of CML progenitors and further augmented their preferential elimination over normal hematopoietic stem and progenitor cells. Thus, our data support the further evaluation of CSL362 therapy in CML.

UR - http://www.scopus.com/inward/record.url?scp=84899137486&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-12-475194

DO - 10.1182/blood-2012-12-475194

M3 - Article

VL - 123

SP - 1218

EP - 1228

JO - Blood

T2 - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -